Scientists spent the next three decades teasing apart the underpinnings of viral biology to create a new generation of vectors. Among these, lentivirus-based vectors, derived from the HIV-1 ...

Retroviral vectors have been very useful for ex vivo gene delivery, but suffer two major limitations: (1) inability to infect post-mitotic cells, and (2) following implantation of the transduced ...

Furthermore, it has been demonstrated that in vivo expression is sustained for several months without detectable pathology. In the original lentivirus vectors described by Naldini et al (Naldini et al ...

A new vector system known as lentiviral vectors can permanently integrate the gene into dividing and non-dividing cells. The capacity of lentiviral vectors to reliably integrate at various genomic ...

Current treatments, including replacement therapies with AAV-based gene therapy ... To overcome these barriers, researchers explored lentiviral vectors, which integrate into the genome and ...

Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies. They are utilised ...

The popularity of viral vector-based gene therapies and vaccines is rapidly growing ... and clarification products to generate lentiviral vectors at the 50-liter scale.

Lentiviral vectors, derived from HIV-1, are widely used in research and clinical applications ... They can provide stable, long-term gene expression but can only infect dividing cells. Retroviral ...

X-linked sideroblastic anemia (XLSA) is a rare genetic disorder caused by mutations in the ALAS2 gene, which plays a critical role in heme biosynthesis within red blood cells.

BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway epithelial ...